A Phase 1B, Multi-center, Open Label, Dose Escalation Study of Mapatumumab ([HGS1012], a Fully-human Monoclonal Antibody to TRAIL-R1) in Combination With Sorafenib as a First Line Therapy in Subjects With Advanced Hepatocellular Carcinoma
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Type, frequency, and severity of adverse events.
Until disease progression or unacceptable toxicity develops
Yes
Norma Lynn Fox, PhD
Study Director
Human Genome Sciences Inc., a GSK Company
United States: Food and Drug Administration
HGS1012-C1077
NCT00712855
June 2008
August 2012
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
University of Florida | Gainesville, Florida 32610-0277 |
UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina |
Cedars-Sinai Health System | Los Angeles, California 90048 |
University of Pennsylvania- Abramson Cancer Center | Philadelphia, Pennsylvania 19104 |